logo-loader
RNS
SkinBioTherapeutics PLC

SkinBioTherapeutics - Update On Board Investigation and Interims Date

RNS Number : 5100X
SkinBioTherapeutics PLC
20 March 2026
 

A blue text on a white background Description automatically generated 

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company" or the "Group")

 

Update On Board Investigation, Interim Results
and Expected Suspension of Trading

 

·      HY26 results to be delayed until Board Investigation is complete

·      Shares expected to be suspended from 1 April 2026 until HY26 results are published

 

20 March 2026 - the Board of SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, updates shareholders on the timing for the interim results for the 6 months ended 31 December 2025 ("Interim Results") and the ongoing Board investigation.

 

As announced on 20 February 2026, the Board appointed FRP Advisory to undertake an independent, forensic review into the matters outlined by the Company on Monday 16 February 2026. Whilst progress is being made, this forensic review is ongoing and accordingly, the Company will not be in a position to announce the Interim Results by 31 March 2026, as required by the AIM Rules for Companies.

 

Consequently, the Board expects that trading in the Company's ordinary shares will be suspended with effect from 7.30am on 1 April 2026. Trading in the shares is anticipated to resume upon the finalisation of the Board investigation and the publication of the Interim Results.

 

The Company has a robust cash position of £2.44m as at the close of 19 March 2026 and its businesses are trading on a "business as usual" basis.

 

The Board will update shareholders on the result of the forensic review and Board investigation as soon as possible.

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

-Ends-

For more information please contact:

SkinBioTherapeutics plc
Martin Hunt, Executive Chairman
Rachel Parsonage, Interim CEO
Emily Bertram, CFO

ir@skinbiotix.com

 

Singer Capital Markets (Nominated Adviser & Broker)
Philip Davies
James Todd
Patrick Weaver

+44 (0) 020 7496 3000

 

Vigo Consulting
Melanie Toyne-Sewell, Rozi Morris

+44 (0) 20 7390 0230
SkinBio@vigoconsulting.com

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBBGDXGDDDGLG
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read